| 1:30 PM - 2:00 PM |
WELCOME - Coffee |
| 2:00 PM - 2:05 PM |
Welcome by the BIRD president |
| 2:05 PM - 3:50 PM |
Session 1: Comorbidities in IBD |
| 2:05 PM - 2:30 PM |
IBD in oncology: to treat or not to treat |
| 2:30 PM - 2:55 PM |
Cardiovascular complications in IBD and impact on the treatment choices |
| 2:55 PM - 3:20 PM |
Short Bowel in IBD: size does matter |
| 3:20 PM - 3:50 PM |
Coffee break & exhibition |
| 3:50 PM - 5:15 PM |
Session 2: Just Arrived |
| 3:50 PM - 4:15 PM |
Monitoring IBD with IBUS |
| 4:15 PM - 4:40 PM |
Positioning of new treatments in 2022 (ozanimod, risankizumab, upadacitinib, filgotinib) |
| 4:40 PM - 5:05 PM |
Surgery in UC: to do or not to do? Case-based discussion |
| 5:05 PM - 5:15 PM |
Closing remarks day 1 |
| 7:00 PM - 12:00 AM |
Networking Event |
| 9:00 AM - 9:05 AM |
Welcome words |
| 9:05 AM - 9:50 AM |
Workshop Session A (choice of 1 of the following 3 options) |
| 9:05 AM - 9:50 AM |
How to use the new molecules (upadacitinib, ozanimod, risankizumab) in clinical practice? |
| 9:05 AM - 9:50 AM |
How and when to switch to SC alternatives (infliximab, vedolizumab)? |
| 9:05 AM - 9:50 AM |
How to optimize the peri-operative approach of my IBD patient? |
| 9:50 AM - 10:05 AM |
Switch rooms |
| 10:05 AM - 10:50 AM |
Workshop session B (choice of 1 of the following 3 options) |
| 10:05 AM - 10:50 AM |
How to use the new molecules (upadacitinib, ozanimod, risankizumab) in clinical practice? |
| 10:05 AM - 10:50 AM |
How and when to switch to SC alternatives (infliximab, vedolizumab)? |
| 10:05 AM - 10:50 AM |
How to optimize the peri-operative approach of my IBD patient? |
| 10:50 AM - 11:10 AM |
Coffee break and exhibition |
| 11:10 AM - 12:10 PM |
Session 3: Best of 2022 |
| 11:10 AM - 11:35 AM |
New in UC: Best of ECCO/DDW/UEGW ‘22 |
| 11:35 AM - 12:00 PM |
New in CD: Best of ECCO/DDW/UEGW ‘22 |
| 12:00 PM - 12:10 PM |
Closing Remarks Day 2 |
| 12:10 PM - 1:10 PM |
Lunch and Exhibition |